At a glance
ClinicalIndex Comparison RecordPhase 3Completed
Drug / intervention
beclomethasone dipropionate plus formoterol fumarate combination +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PARALLEL-GROUP DESIGN CLINICAL TRIAL OF THE EFFICACY AND TOLERABILITY OF CHF 1535 (BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg) pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI (SERETIDE®) IN THE 12-WEEK TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE PERSISTENT ASTHMA
In Brief
A Phase 3 clinical trial evaluating beclomethasone dipropionate plus formoterol fumarate combination and fluticasone propionate plus salmeterol xinafoate combination for Bronchial Asthma. Completed, across 12 sites in 2 countries.
Detailed Summary
The aim of this study was to compare the efficacy and tolerability of the fixed combination beclomethasone/formoterol pMDI with that of fluticasone/salmeterol pMDI in patients with moderate to severe asthma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchial Asthma
CountriesPoland, Ukraine
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2004
Study CompletionSep 2005
First PostedNov 2006
TodayJul 2026
First PostedNov 1, 2006
Enrollment StartNov 1, 2004
Study CompletionSep 1, 2005
TodayJul 2, 2026
Posted 19.7 years ago
Interventions
beclomethasone dipropionate plus formoterol fumarate combinationdrug
fluticasone propionate plus salmeterol xinafoate combinationdrug